Sign in or Register   Sign in or Register
  |  

Mouse Anti-NLRP1 Recombinant Antibody (CBWJN-0715) (CBMAB-N0413-WJ)

This product is a Mouse antibody that recognizes NLRP1. The antibody CBWJN-0715 can be used for immunoassay techniques such as: WB, IHC, ICC, IP.
See all NLRP1 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBWJN-0715
Antibody Isotype
IgG1
Application
WB, IHC, ICC, IP

Basic Information

Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS
Preservative
0.02% sodium azide
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
NLR Family Pyrin Domain Containing 1
Introduction
This gene encodes a member of the Ced-4 family of apoptosis proteins. Ced-family members contain a caspase recruitment domain (CARD) and are known to be key mediators of programmed cell death. The encoded protein contains a distinct N-terminal pyrin-like motif, which is possibly involved in protein-protein interactions. This protein interacts strongly with caspase 2 and weakly with caspase 9. Overexpression of this gene was demonstrated to induce apoptosis in cells. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found for this gene, but the biological validity of some variants has not been determined. [provided by RefSeq, Jul 2008]
Entrez Gene ID
UniProt ID
Alternative Names
NLR Family Pyrin Domain Containing 1; Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat And Pyrin Domain Containing 1; NACHT, Leucine Rich Repeat And PYD (Pyrin Domain) Containing 1; Death Effector Filament-Forming Ced-4-Like Apoptosis Protein; Nucleotide-Binding Domain And Caspase Recruitment Domain; Caspase Recruitment Domain-Containing Protein 7; DEFCAP; NALP1; CARD7; NAC; Systemic Lupus Erythematosus, Vitiligo-Related 1; NACHT, LRR And PYD Domains-Containing Protein 1; NACHT, Leucine Rich Repeat And PYD Containing 1;
Function
Acts as the sensor component of the NLRP1 inflammasome, which mediates inflammasome activation in response to various pathogen-associated signals, leading to subsequent pyroptosis (PubMed:22665479, PubMed:12191486, PubMed:17349957, PubMed:27662089, PubMed:31484767, PubMed:33093214, PubMed:33731929, PubMed:33731932).
Inflammasomes are supramolecular complexes that assemble in the cytosol in response to pathogens and other damage-associated signals and play critical roles in innate immunity and inflammation (PubMed:22665479, PubMed:12191486, PubMed:17349957).
Acts as a recognition receptor (PRR): recognizes specific pathogens and other damage-associated signals, such as cleavage by human rhinoviruses 14 and 16 (HRV-14 and HRV-16), double-stranded RNA or Val-boroPro inhibitor, and mediates the formation of the inflammasome polymeric complex composed of NLRP1, CASP1 and PYCARD/ASC (PubMed:22665479, PubMed:12191486, PubMed:17349957, PubMed:30291141, PubMed:33243852, PubMed:33093214).
In response to pathogen-associated signals, the N-terminal part of NLRP1 is degraded by the proteasome, releasing the cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-containing protein 1, C-terminus), which polymerizes and associates with PYCARD/ASC to initiate the formation of the inflammasome complex: the NLRP1 inflammasome recruits pro-caspase-1 (proCASP1) and promotes caspase-1 (CASP1) activation, which subsequently cleaves and activates inflammatory cytokines IL1B and IL18 and gasdermin-D (GSDMD), leading to pyroptosis (PubMed:22665479, PubMed:12191486, PubMed:17349957, PubMed:32051255, PubMed:33093214).
Activation of NLRP1 inflammasome is also required for HMGB1 secretion; the active cytokines and HMGB1 stimulate inflammatory responses (PubMed:22801494).
Binds ATP and shows ATPase activity (PubMed:11113115, PubMed:15212762, PubMed:33243852).
Plays an important role in antiviral immunity and inflammation in the human airway epithelium (PubMed:33093214).
Specifically recognizes a number of pathogen-associated signals: upon infection by human rhinoviruses 14 and 16 (HRV-14 and HRV-16), NLRP1 is cleaved and activated which triggers NLRP1-dependent inflammasome activation and IL18 secretion (PubMed:33093214).
Positive-strand RNA viruses such as. Semliki forest virus and long dsRNA activate the NLRP1 inflammasome, triggering IL1B release in a NLRP1-dependent fashion (PubMed:33243852).
Acts as a direct sensor for long dsRNA and thus RNA virus infection (PubMed:33243852).
May also be activated by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, in a NOD2-dependent manner (PubMed:18511561).
NACHT, LRR and PYD domains-containing protein 1
Constitutes the precursor of the NLRP1 inflammasome, which mediates autoproteolytic processing within the FIIND domain to generate the N-terminal and C-terminal parts, which are associated non-covalently in absence of pathogens and other damage-associated signals.
NACHT, LRR and PYD domains-containing protein 1, N-terminus
Regulatory part that prevents formation of the NLRP1 inflammasome: in absence of pathogens and other damage-associated signals, interacts with the C-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus), preventing activation of the NLRP1 inflammasome (PubMed:33093214).
In response to pathogen-associated signals, this part is ubiquitinated and degraded by the proteasome, releasing the cleaved C-terminal part of the protein, which polymerizes and forms the NLRP1 inflammasome (PubMed:33093214).
NACHT, LRR and PYD domains-containing protein 1, C-terminus
Constitutes the active part of the NLRP1 inflammasome (PubMed:33093214, PubMed:33731929, PubMed:33731932).
In absence of pathogens and other damage-associated signals, interacts with the N-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, N-terminus), preventing activation of the NLRP1 inflammasome (PubMed:33093214).
In response to pathogen-associated signals, the N-terminal part of NLRP1 is degraded by the proteasome, releasing this form, which polymerizes and associates with PYCARD/ASC to form of the NLRP1 inflammasome complex: the NLRP1 inflammasome complex then directly recruits pro-caspase-1 (proCASP1) and promotes caspase-1 (CASP1) activation, leading to gasdermin-D (GSDMD) cleavage and subsequent pyroptosis (PubMed:33093214).
Isoform 2
It is unclear whether is involved in inflammasome formation. It is not cleaved within the FIIND domain, does not assemble into specks, nor promote IL1B release (PubMed:22665479).
However, in an vitro cell-free system, it has been shown to be activated by MDP (PubMed:17349957).
Biological Process
Activation of cysteine-type endopeptidase activity involved in apoptotic processManual Assertion Based On ExperimentIDA:HGNC-UCL
Antiviral innate immune responseManual Assertion Based On ExperimentIDA:UniProtKB
Aapoptotic process1 PublicationNAS:UniProtKB
Defense response to bacteriumISS:BHF-UCL
Defense response to virusManual Assertion Based On ExperimentIDA:UniProtKB
Inflammatory responseIEA:UniProtKB-KW
Neuron apoptotic processManual Assertion Based On ExperimentIDA:HGNC-UCL
NLRP1 inflammasome complex assemblyManual Assertion Based On ExperimentIMP:UniProtKB
Pattern recognition receptor signaling pathway1 PublicationIC:ComplexPortal
Positive regulation of inflammatory responseManual Assertion Based On ExperimentIDA:ComplexPortal
Positive regulation of interleukin-1 beta productionManual Assertion Based On ExperimentIDA:UniProtKB
Protein homooligomerizationManual Assertion Based On ExperimentIDA:UniProtKB
PyroptosisManual Assertion Based On ExperimentIDA:UniProtKB
Regulation of apoptotic processIEA:InterPro
Regulation of inflammatory response1 PublicationIC:BHF-UCL
Response to muramyl dipeptideISS:BHF-UCL
Self proteolysisManual Assertion Based On ExperimentIDA:UniProtKB
Cellular Location
Cytoplasm, cytosol
Cytoplasm
Nucleus
Nucleocytoplasmic distribution in lymphoid organs (probably in T-cells) and in neurons. In epithelial cells, predominantly cytoplasmic.
NACHT, LRR and PYD domains-containing protein 1, C-terminus
Inflammasome
Involvement in disease
Vitiligo-associated multiple autoimmune disease 1 (VAMAS1):
A disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.
Palmoplantar carcinoma, multiple self-healing (MSPC):
An autosomal dominant disease characterized by keratopathy with neovascularization, bilateral corneal opacification, palmoplantar hyperkeratosis, dyshidrosis, dystrophic nails, and recurrent keratoacanthomas in palmoplantar skin as well as in conjunctival and corneal epithelia. In addition, patients experience a high susceptibility to malignant squamous cell carcinoma.
Autoinflammation with arthritis and dyskeratosis (AIADK):
A disorder characterized by recurrent fever, diffuse skin dyskeratosis, autoinflammation, autoimmunity, arthritis and high transitional B-cell level. Inheritance can be autosomal dominant or autosomal recessive.
Respiratory papillomatosis, juvenile recurrent, congenital (JRRP):
An autosomal recessive disease characterized by recurrent growth of papillomas in the respiratory tract, and onset in early childhood. Papillomas are most commonly found in the larynx but may occur anywhere from the mouth to the bronchi. Children typically present within the first years of life with hoarseness or, in more severe cases, respiratory distress or stridor and airway obstruction. JRRP is associated with infection of the upper airway by human papillomaviruses of the alpha genus. The infection is thought to occur by vertical transmission at birth.
PTM
NACHT, LRR and PYD domains-containing protein 1
Autocatalytically cleaved (PubMed:22087307, PubMed:22665479, PubMed:33093214).
Autocatalytic cleavage in FIIND region occurs constitutively, prior to activation signals, and is required for inflammasome activity (IL1B release), possibly by facilitating CASP1 binding (PubMed:22087307, PubMed:22665479, PubMed:33093214).
Both N- and C-terminal parts remain associated non-covalently (PubMed:22087307, PubMed:22665479, PubMed:33093214).
NACHT, LRR and PYD domains-containing protein 1, N-terminus
Ubiquitinated by the cullin:ZER1/ZYG11B complex in response to pathogen-associated signals, leading to its degradation by the proteasome and subsequent release of the cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-containing protein 1, C-terminus), which polymerizes and forms the NLRP1 inflammasome.
(Microbial infection) Cleaved between Gln-130 and Gly-131 by human rhinovirus 14 (HRV-14) Protease 3C. This cleavage triggers N-glycine-mediated proteasomal degradation of the autoinhibitory NLRP1 N-terminal fragment via the cullin:ZER1/ZYG11B complex which liberates the activating C-terminal fragment and activates NLRP1 inflammasome.

Gong, Q., Robinson, K., Xu, C., Huynh, P. T., Chong, K. H. C., Tan, E. Y. J., ... & Wu, B. (2021). Structural basis for distinct inflammasome complex assembly by human NLRP1 and CARD8. Nature communications, 12(1), 188.

Tsu, B. V., Beierschmitt, C., Ryan, A. P., Agarwal, R., Mitchell, P. S., & Daugherty, M. D. (2021). Diverse viral proteases activate the NLRP1 inflammasome. Elife, 10, e60609.

Huang, M., Zhang, X., Toh, G. A., Gong, Q., Wang, J., Han, Z., ... & Chai, J. (2021). Structural and biochemical mechanisms of NLRP1 inhibition by DPP9. Nature, 592(7856), 773-777.

Bauernfried, S., & Hornung, V. (2021). Human NLRP1: From the shadows to center stage. Journal of Experimental Medicine, 219(1), e20211405.

Bauernfried, S., Scherr, M. J., Pichlmair, A., Duderstadt, K. E., & Hornung, V. (2021). Human NLRP1 is a sensor for double-stranded RNA. Science, 371(6528), eabd0811.

Hollingsworth, L. R., Sharif, H., Griswold, A. R., Fontana, P., Mintseris, J., Dagbay, K. B., ... & Wu, H. (2021). DPP9 sequesters the C terminus of NLRP1 to repress inflammasome activation. Nature, 592(7856), 778-783.

Taabazuing, C. Y., Griswold, A. R., & Bachovchin, D. A. (2020). The NLRP1 and CARD8 inflammasomes. Immunological reviews, 297(1), 13-25.

Fenini, G., Karakaya, T., Hennig, P., Di Filippo, M., & Beer, H. D. (2020). The NLRP1 inflammasome in human skin and beyond. International journal of molecular sciences, 21(13), 4788.

Sandstrom, A., Mitchell, P. S., Goers, L., Mu, E. W., Lesser, C. F., & Vance, R. E. (2019). Functional degradation: A mechanism of NLRP1 inflammasome activation by diverse pathogen enzymes. Science, 364(6435), eaau1330.

Mitchell, P. S., Sandstrom, A., & Vance, R. E. (2019). The NLRP1 inflammasome: new mechanistic insights and unresolved mysteries. Current Opinion in Immunology, 60, 37-45.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-NLRP1 Recombinant Antibody (CBWJN-0715)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare